Evidence mapPaperPMID 35002736Full record

ArticleFrontiers in pharmacology2021

What Is Valued Most by Patients With Type 2 Diabetes Mellitus When Selecting Second-Line Antihyperglycemic Medications in China.

Shimeng Liu, Jing Liu, Yijiang Yu, Lei Si, Chengxiang Tang, Zhigang Liu, Yingyao Chen

Abstract read
In one paragraph

Article in Frontiers in pharmacology, 2021. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Assessing patient information needs for new antidiabetic medications to inform shared decision-making: A best-worst scaling experiment in China.Health expectations : an international journal of public participation in health care and health policy · 2024
    Article
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

7 authors.

Shimeng LiuSchool of Public Health, Fudan University, Shanghai, China.
Jing LiuSchool of Management, Hainan Medical University, Haikou, China.
Yijiang YuHuai'an Hospital of Traditional Chinese Medicine, Huai'an, China.
Lei SiThe George Institute for Global Health, UNSW Sydney, Kensington, NSW, Australia.
Chengxiang TangSchool of Public Administration, Guangzhou University, Guangzhou, China.
Zhigang LiuSchool of Management, Hainan Medical University, Haikou, China.
Yingyao ChenSchool of Public Health, Fudan University, Shanghai, China.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

best-worst scalingChinapatient preferencessecond-line antihyperglycemic medicationstype 2 diabetes mellitus

Identifiers

PMID35002736
PMCPMC8733399

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.